No Data Yet
The global drug delivery devices market is projected to reach US$450.7 billion by 2035, spurred by surging revenues from biologic drugs that are fueling multi-billion dollar investments in manufacturing capacity from pharmaceutical leaders.
Stock analysis reveals Hologic's free cash flow margin shrank by 20.6 percentage points, while McDonald's boasts a 57% gross margin, highlighting a performance divergence in the S&P 500.
The surging market for GLP-1 obesity drugs is creating a significant downstream opportunity for key suppliers of injectable delivery systems. West Pharmaceutical is strategically positioned to capitalize on this trend through its portfolio of High-Value Product (HVP) components, though it faces broader manufacturing headwinds.